Baxdrostat vs VB19055

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

Baxdrostat · Baxfendy

Marketed by AstraZeneca and partners

Approved in Hypertensionsmall molecule
Reliable signal

NCT06034743 · Phase 3 · completed

The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.

Next expected readout: December 2026 · NCT07222917 (registry estimate)

Reported efficacy

Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy (Baseline to week 12): Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). (met)

Result source: NCT06168409

VB19055

Developed by Yangli Pharmaceutical Technology

Phase 2 in Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07833098 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBaxdrostatVB19055
Seated SBP, change-15.7 vs -5.8−9.9 vs placebo2 mg · wk 12 · n 266NCT06034743
7 other results
  • -14.5 vs -5.8 1 mg · wk 12 · n 264 · Phase 3 · primary NCT06034743
  • -3.7 vs 1.4 2 mg · wk 32 · n 172 · Phase 3 · secondary NCT06034743
  • -15.2 vs -5.4 2 mg · wk 12 · n 199 · Phase 3 · secondary NCT06034743
  • -14.9 vs -4.7 2 mg · wk 12 · n 108 · Phase 3 · secondary NCT06168409
  • -11.6 vs -2.4 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -12.1 vs -1.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -14.5 vs -5.4 1 mg · wk 12 · n 187 · Phase 3 · secondary NCT06034743
—Not reported
24-hour ambulatory SBP, change-16.6 vs -2.6−14 vs placebo2 mg · wk 12 · n 89NCT06168409—Not reported
Seated DBP, change-6.9 vs -3−3.9 vs placebo2 mg · wk 12 · n 266NCT06034743
4 other results
  • -7.6 vs -2.6 2 mg · wk 12 · n 107 · Phase 3 · secondary NCT06168409
  • -6.1 vs -0.5 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -5.4 vs 0.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -6.3 vs -3 1 mg · wk 12 · n 264 · Phase 3 · secondary NCT06034743
—Not reported

Seated SBP, change

Baxdrostat
-15.7 vs -5.8−9.9 vs placebo2 mg · wk 12 · n 266NCT06034743
7 other results
  • -14.5 vs -5.8 1 mg · wk 12 · n 264 · Phase 3 · primary NCT06034743
  • -3.7 vs 1.4 2 mg · wk 32 · n 172 · Phase 3 · secondary NCT06034743
  • -15.2 vs -5.4 2 mg · wk 12 · n 199 · Phase 3 · secondary NCT06034743
  • -14.9 vs -4.7 2 mg · wk 12 · n 108 · Phase 3 · secondary NCT06168409
  • -11.6 vs -2.4 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -12.1 vs -1.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -14.5 vs -5.4 1 mg · wk 12 · n 187 · Phase 3 · secondary NCT06034743
VB19055
—Not reported

24-hour ambulatory SBP, change

Baxdrostat
-16.6 vs -2.6−14 vs placebo2 mg · wk 12 · n 89NCT06168409
VB19055
—Not reported

Seated DBP, change

Baxdrostat
-6.9 vs -3−3.9 vs placebo2 mg · wk 12 · n 266NCT06034743
4 other results
  • -7.6 vs -2.6 2 mg · wk 12 · n 107 · Phase 3 · secondary NCT06168409
  • -6.1 vs -0.5 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -5.4 vs 0.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -6.3 vs -3 1 mg · wk 12 · n 264 · Phase 3 · secondary NCT06034743
VB19055
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VB19055: no structured comparison results are available for Hypertension.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Baxdrostat: 3 of 4 rows · VB19055: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBaxdrostat
Dropout rate
10.9%2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
7.2%1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
5.5%2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
6.3%2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
Serious AEs
3.4%2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
2.3%2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
4.8%2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
1.9%1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
0.9%2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
0%2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
2 mga
hyperkalaemia 11.7% (placebo 2.7%)
hyponatraemia 3.8% (placebo 0.8%)
muscle spasms 3.8% (placebo 0.4%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
2 mg
hyperkalaemia 9.9% (placebo 2.7%)
hyponatraemia 3.5% (placebo 0.8%)
nasopharyngitis 1.7% (placebo 2.3%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
hyperkalaemia 16.1% (placebo 2.7%)
hyponatraemia 11.3% (placebo 0.8%)
muscle spasms 6.5% (placebo 0.4%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
1 mg
hyperkalaemia 6.1% (placebo 2.7%)
nasopharyngitis 3% (placebo 2.3%)
upper respiratory tract infection 2.7% (placebo 3.8%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
hyperkalaemia 10.2% (placebo 2.8%)
headache 5.6% (placebo 2.8%)
hypotension 4.6% (placebo 0%)
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
dizziness 6.3% (placebo 6.3%)
nausea 6.3% (placebo 0%)
vomiting 6.3% (placebo 0%)
NCT06336356 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Baxdrostat

Seated SBP -3.7 vs 1.4 placebo mmHg @ 32wk2 mg
absolute change · mmHg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 7 more results
-15.2 vs -5.4 placebo mmHg @ 12wk2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-15.7 vs -5.8 placebo mmHg @ 12wk2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-14.9 vs -4.7 placebo mmHg @ 12wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-12.1 vs -1.1 placebo mmHg @ 4wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-11.6 vs -2.4 placebo mmHg @ 8wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-14.5 vs -5.4 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-14.5 vs -5.8 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
Seated DBP -6.9 vs -3 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 4 more results
-7.6 vs -2.6 placebo mmHg @ 12wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-5.4 vs 0.1 placebo mmHg @ 4wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-6.1 vs -0.5 placebo mmHg @ 8wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-6.3 vs -3 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
Seated SBP Control 40% (n=265) vs 18.7% (n=262) placebo @ 12wk2 mg
event count · % of participants
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 106 Participants as posted
show 1 more result
39.4% (n=264) vs 18.7% (n=262) placebo @ 12wk*1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 104 Participants as posted
Ambulatory SBP -16.6 vs -2.6 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Night SBP -16 vs -2.1 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Day SBP -16.8 vs -2.7 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory SBP Control 70.6% (n=85) vs 16.7% (n=84) placebo @ 12wk2 mg
event count · % of participants
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 60 Participants as posted
Ambulatory DBP -8.3 vs -1.5 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Night DBP -7.9 vs -1.1 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Day DBP -8.4 vs -1.7 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Nocturnal SBP Dipping 40.4% (n=89) vs 29.5% (n=95) placebo @ 12wk2 mg
event count · % of participants
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 36 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · VB19055's landscape